Pair page
Survodutide with Tirzepatide
Mechanism-tag overlap and published literature for Survodutide and Tirzepatide, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
glucagon-glp-1-receptor-dual-agonist
dual-gip-glp-1-receptor-agonist
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Survodutide and Tirzepatide have published these mechanism-level observations. Not a co-administration recommendation.
Tirzepatide is a GLP-1 / GIP dual agonist. Mechanistically non-overlapping with survodutide's glucagon arm. Phase 3 head-to-head data between survodutide and tirzepatide will determine obesity positioning; survodutide's glucagon arm may be more differentiating in MASH and hepatic-fat-dominant disease than in pure weight-loss efficacy.
Quick facts
Survodutide
Tirzepatide
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2024 | Survodutide | Wharton S, le Roux CW, Kosiborod MN, et al. Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE-1 and -2). Obesity (Silver Spring). 2024. | human trial, Phase 3 |
| 2023 | Survodutide | Boehringer Ingelheim. Phase III studies — survodutide in obesity and overweight. Boehringer Ingelheim corporate press release and investor materials, 2023–2025. | human trial, Phase 3 |
| 2025 | Survodutide | Le Roux CW, et al. Survodutide, a glucagon receptor/glucagon-like peptide-1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo-controlled, dose-finding, phase 2 trial. Diabetes Obes Metab. 2025. doi:10.1111/dom.1… | human trial, Phase 2 |
| 2024 | Survodutide | Le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024;12(3):162-173. doi:10.1016/S2213-8587(… | human trial, Phase 2 |
| 2024 | Survodutide | Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, Anstee QM, Hussain SA, Martins EB, Walker M, Oldham P, Starova B, Ogawa W, Wong VW, Ratziu V, Younes R, Hosseini-Tabatabaei A, Loomba R. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J M… PMID 38847460 | human trial, Phase 2 |
| 2023 | Survodutide | Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML; Retatrutide Phase 2 Obesity Trial Investigators. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315. (F… PMID 37366315 | human trial, Phase 2 |
| — | Survodutide | ClinicalTrials.gov. NCT04667377 (Phase 2 obesity); NCT04771273 (Phase 2 MASH, study 1404-0043); NCT06066879 (SYNCHRONIZE-1); NCT06066892 (SYNCHRONIZE-2). | human trial, Phase 2 |
| 2023 | Survodutide | Jungnik A, Arrubla Martinez J, Plum-Mörschel L, Kapitza C, Lamers D, Thamer C, Unseld A, Hennige AM. Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906. Diabetes Obes… | human trial, Phase 1 |
| 2016 | Survodutide | Tschöp MH, Finan B, Clemmensen C, Gelfanov V, Perez-Tilve D, Müller TD, DiMarchi RD. Unimolecular polypharmacy for treatment of diabetes and obesity. Cell Metab. 2016;24(1):51-62. PMID: 27411008. (Foundational review on multi-receptor agonism rationale including GLP-1/glucagon.) PMID 27411008 | human study |
| 2022 | Survodutide | Zimmermann T, Thomas L, Baader-Pagler T, Haebel P, Simon E, Reindl W, Bajrami B, Rist W, Uphues I, Drucker DJ, Klein H, Santhanam R, Hennige AM, Hamilton B, Hennig R, Dux M, Hamprecht B, Bierwisch D, Neubauer H, Tschank G, Stengelin S, Redemann N, Wiedenmann A, Pagler T, et al.… | preclinical, in vivo |
| 2024 | Survodutide | Loomba R, Hartman ML, Sanyal AJ. Two Trials of Therapeutics for MASH with Liver Fibrosis. Reply. N Engl J Med. 2024;391(15):1462-1463. PMID: 39413388. PMID 39413388 | research article |
| 2024 | Survodutide | Polyzos SA. Two Trials of Therapeutics for MASH with Liver Fibrosis. N Engl J Med. 2024;391(15):1461. PMID: 39413385. PMID 39413385 | research article |
| 2022 | Tirzepatide | Heerspink HJL, Sattar N, Pavo I, Haupt A, Duffin KL, Yang Z, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(11)… PMID 36152639 | human trial, Phase 3 |
| 2021 | Tirzepatide | Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, et al.; SURPASS-1 Investigators. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet.… PMID 34186022 | human trial, Phase 3 |
| 2021 | Tirzepatide | Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, Brown K, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group,… PMID 34370970 | human trial, Phase 3 |
| 2021 | Tirzepatide | Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, et al.; SURPASS-4 Investigators. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 202… PMID 34672967 | human trial, Phase 3 |
| 2025 | Tirzepatide | Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, et al.; SURMOUNT-1 Investigators. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025;392(10):958-971. PMID: 39536238. PMID 39536238 | human trial |
| 2024 | Tirzepatide | Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, et al.; SURMOUNT-4 Investigators. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. PMID: 38078870. PMID 38078870 | human trial |
| 2024 | Tirzepatide | Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, et al.; SURMOUNT-OSA Investigators. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391(13):1193-1205. PMID: 38912654. PMID 38912654 | human trial |
| 2023 | Tirzepatide | Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, et al.; SURMOUNT-2 Investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626. PMID: 37385275. PMID 37385275 | human trial |
| 2022 | Tirzepatide | Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al.; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024. PMID 35658024 | human trial |
| 2022 | Tirzepatide | Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, Rodríguez Á. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022;327(6):534-545. PMID: 3513… PMID 35133415 | human trial |
| 2021 | Tirzepatide | Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al.; SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. PMID: 34170647. PMID 34170647 | human trial |
| 2018 | Tirzepatide | Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. PMID: 30473097. PMID 30473097 | mechanism / discovery |
Related pair pages
More research context
Frequently asked
Have Survodutide and Tirzepatide been studied together?
Researchers have published mechanistic-level co-administration discussion of Survodutide and Tirzepatide. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Survodutide and Tirzepatide share?
Survodutide and Tirzepatide do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Survodutide and Tirzepatide?
Survodutide: Not approved; Phase 3. Tirzepatide: Approved (T2D 2022, obesity 2023, OSA 2024). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Survodutide and Tirzepatide?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Survodutide profile and the Tirzepatide profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026